JL-15003 / Jecho Biopharma - LARVOL DELTA

Safety, Efficacy, and Genetic Profiling of JL15003 in Recurrent Glioblastoma: A Single-arm Open-label Phase I Clinical Trial (SNO 2025) - "The study demonstrates that JL15003 is safe and well tolerated in patients with rGBM and the preliminary efficacy has been shown. In addition, the genetic profiling by single cell seq and RNA Seq provides the data for mechanism analysis and proposes the multi-dose administration of JL15003 and the biomarkers for next trial design in patients with rGBM."

Clinical • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Solid Tumor

Safety, Efficacy, and Genetic Profiling of JL15003 in Recurrent Glioblastoma: A Single-arm Open-label Phase I Clinical Trial (SNO 2025) - "The study demonstrates that JL15003 is safe and well tolerated in patients with rGBM and the preliminary efficacy has been shown. In addition, the genetic profiling by single cell seq and RNA Seq provides the data for mechanism analysis and proposes the multi-dose administration of JL15003 and the biomarkers for next trial design in patients with rGBM."

Clinical • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Solid Tumor

Safety, Efficacy, and Genetic Profiling of JL15003 in Recurrent Glioblastoma: A Single-arm Open-label Phase I Clinical Trial (WFNOS 2025) - "The study demonstrates that JL15003 is safe and well tolerated in patients with rGBM and the preliminary efficacy has been shown. In addition, the genetic profiling by single cell seq and RNA Seq provides the data for mechanism analysis and proposes the multi-dose administration of JL15003 and the biomarkers for next trial design in patients with rGBM."

Clinical • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Safety, Efficacy, and Genetic Profiling of JL15003 in Recurrent Glioblastoma: A Single-arm Open-label Phase I Clinical Trial (WFNOS 2025) - P1 | "The study demonstrates that JL15003 is safe and well tolerated in patients with rGBM and the preliminary efficacy has been shown. In addition, the genetic profiling by single cell seq and RNA Seq provides the data for mechanism analysis and proposes the multi-dose administration of JL15003 and the biomarkers for next trial design in patients with rGBM."

Clinical • IO biomarker • P1 data • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

Today!...new domestic drugs have been granted Breakthrough Therapy Designation by CDE, namely cell therapy, oncolytic virus... [Google translation] (bydrug.pharmcube.com) - "On December 4, the official website of CDE showed that three innovative drugs, anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T therapy, Yongterike), JL15003 injection (oncolytic virus product, JIKE Biotech)...are proposed to be included in breakthrough therapies. Anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (aka CAR-T-19) is a cellular immunotherapy drug that integrates single-chain antibodies that recognize CD19-specific B-cell antigens into the patient's own T cells by means of genetic engineering, and the T cells have the ability to kill CD19-expressing B-cell tumors after reinfusion, so as to achieve the purpose of treating B-cell malignant hematologic diseases. According to public information....phase I clinical trial for the treatment of glioblastoma is currently underway."

Breakthrough therapy • CNS Tumor • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor